消癌平注射液联合SOX化疗方案对中晚期三阴性乳腺癌患者近期预后的影响

Effect Analysis of SOX Regimen and Xiaoaiping Injection on Short-term Prognosis in Patients with Advanced Triple-negative Breast Cancer

目的:分析消癌平注射液联合SOX化疗方案对中晚期三阴性乳腺癌患者近期预后的影响。方法:本研究采取回顾性分析的方法,收集2016年8月-2018年8月医院收治的中晚期三阴性乳腺癌患者67例,根据不同治疗方案分为两组:常规组(n=33)接受奥沙利铂联合替吉奥(SOX)方案治疗,观察组(n=34)接受消癌平注射液联合SOX方案治疗。4个周期后,比较两组患者的临床疗效;随访至2019年8月,通过Kaplan-Meier生存函数分析两组患者的生存期。结果:治疗4个周期后,观察组客观缓解率、临床控制率分别为41.18%和82.35%,常规组分别为30.30%和60.61%,观察组临床控制率明显高于常规组,差异有统计学意义(P<0.05),两组患者客观缓解率比较差异无统计学意义(P>0.05);随访至2019年8月,观察组中位生存期为24个月,常规组为18个月;两组患者不良反应发生率比较差异均无统计学意义(P>0.05)。结论:消癌平注射液联合SOX方案化疗提高了中晚期三阴性乳腺癌疾病控制效果,延长了患者生存期,且未加重不良反应。

Objective:To analyze the effect of SOX regimen and Xiaoaiping Injection on short-term prognosis in patients with advanced triple-negative breast cancer.Method:Retrospective analysis was used in this study,from August 2016 to August 2018,67 patients with advanced triple-negative breast cancer were collected,the patients were divided into two groups according to different treatment,the conventional group (n=33) received Oxaliplatin combined with S-1 (SOX),the observation group (n=34) received SOX regimen and Xiaoaiping Injection.After 4 cycles of chemotherapy,the clinical efficacy were compared between the two group.The patients were followed up to August 2019,the two groups of survival were analyzed by the Kaplan-Meier survival function.Result:After 4 cycles of chemotherapy,the objective remission rate and the clinical control rate of the observation group were 41.18% and 82.35% respectively,the conventional group were 30.30% and 60.61% respectively,the clinical control rate of the observation group was higher than that of the conventional group,the difference was statistically significant (P<0.05),there was no significant difference between the two groups in objective remission rate (P>0.05).The patients were followed up to August 2019,the median survival time was 24 months in the observation group,the conventional group was 18 months;there was no significant difference between the two groups in incidence of adverse reactions (P>0.05).Conclusion:Xiaoaiping Injection combined with SOX chemotherapy improves in advanced triple-negative breast cancer control effect,prolong the patient of survival,the adverse reactions can be tolerated.